title: Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
abstract: OBJECTIVE
  Romidepsin is a potent histone deacetylase inhibitor under clinical development. The objective of this study was to evaluate the effect of demographic, clinical, and pharmacogenetic covariates on the pharmacokinetics of romidepsin in patients with T-cell lymphoma.
  
  
  METHODS
  Pharmacokinetic assessment was done in 98 patients enrolled in a phase II study who received 14 or 18 mg/m2 of romidepsin as a 4-hour infusion on day 1 during their first treatment cycle. Population modeling was done using a nonlinear mixed effects modeling approach to explore the effects of polymorphic variations in CYP3A4, CYP3A5, SLCO1B3, and ABCB1, all of which encode genes thought to be involved in romidepsin disposition.
  
  
  RESULTS
  A two-compartment model with linear kinetics adequately described the romidepsin disposition. Population clearance was 15.9 L/h with between-patient variability of 37%. ABCB1 2677G>T/A variant alleles tended toward a reduced clearance and lower volume of tissue distribution, but this was not supported by a statistical significance. Genetic variations in CYP3A4/5 and SCLO1B3 had no effect on the systemic exposure.
  
  
  CONCLUSIONS
  The population pharmacokinetic analysis indicates moderate interindividual variability in romidepsin pharmacokinetics and no clinically relevant covariates associated with the unexplained pharmacokinetic variability of romidepsin in this population.
authors.affiliation: Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
authors.forename: Sukyung
authors.initials: S
authors.lastname: Woo
authors.forename: Erin R
authors.initials: ER
authors.lastname: Gardner
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Chen
authors.forename: Sandra B
authors.initials: SB
authors.lastname: Ockers
authors.forename: Caitlin E
authors.initials: CE
authors.lastname: Baum
authors.forename: Tristan M
authors.initials: TM
authors.lastname: Sissung
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Price
authors.forename: Robin
authors.initials: R
authors.lastname: Frye
authors.forename: Richard L
authors.initials: RL
authors.lastname: Piekarz
authors.forename: Susan E
authors.initials: SE
authors.lastname: Bates
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics*; D047630:Depsipeptides / Q000493:pharmacokinetics*; D005260:Female; D005838:Genotype; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000903:Antibiotics, Antineoplastic; D047630:Depsipeptides; C087123:romidepsin